Cargando…
Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis
OBJECTIVE: The need for and efficacy of immunomodulators for maintaining remission after tacrolimus therapy have not been sufficiently defined. This study evaluated the efficacy of immunomodulators for maintaining remission in patients with ulcerative colitis after tacrolimus therapy. METHODS: Patie...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746627/ https://www.ncbi.nlm.nih.gov/pubmed/31118391 http://dx.doi.org/10.2169/internalmedicine.2632-19 |
_version_ | 1783451716168974336 |
---|---|
author | Nishida, Yu Hosomi, Shuhei Yamagami, Hirokazu Sugita, Naoko Itani, Shigehiro Yukawa, Tomomi Otani, Koji Nagami, Yasuaki Tanaka, Fumio Taira, Koichi Kamata, Noriko Kakimoto, Kazuki Tanigawa, Tetsuya Watanabe, Toshio Fujiwara, Yasuhiro |
author_facet | Nishida, Yu Hosomi, Shuhei Yamagami, Hirokazu Sugita, Naoko Itani, Shigehiro Yukawa, Tomomi Otani, Koji Nagami, Yasuaki Tanaka, Fumio Taira, Koichi Kamata, Noriko Kakimoto, Kazuki Tanigawa, Tetsuya Watanabe, Toshio Fujiwara, Yasuhiro |
author_sort | Nishida, Yu |
collection | PubMed |
description | OBJECTIVE: The need for and efficacy of immunomodulators for maintaining remission after tacrolimus therapy have not been sufficiently defined. This study evaluated the efficacy of immunomodulators for maintaining remission in patients with ulcerative colitis after tacrolimus therapy. METHODS: Patients with active ulcerative colitis who started oral tacrolimus between January 2009 and September 2017 and were responsive were retrospectively evaluated. Long-term outcomes were compared using Cox proportional hazard regression with inverse probability of treatment weighting. RESULTS: Among the 63 patients in the study, 45 received immunomodulators. During the follow-up, 30 patients (47.6%) experienced a relapse. The relapse-free survival rate was significantly worse in the group that did not receive immunomodulators than in those that did (p=0.01, log-rank test); the 2-year relapse-free rates were 22.5% and 63.6% in the non-immunomodulator and immunomodulator groups, respectively. A multivariate analysis showed immunomodulator treatment to be an independent protective factor for clinical relapse (adjusted hazard ratio: 0.35, 95% confidence interval: 0.16-0.78, p=0.01). A Cox regression analysis using inverse probability of treatment weighting also showed that immunomodulator maintenance therapy was correlated with a longer relapse-free survival (hazard ratio: 0.31, 95% confidence interval: 0.15-0.64, p<0.01), A similar response was also observed in non-steroid-dependent patients (hazard ratio: 0.36, 95% confidence interval: 0.14-0.99, p=0.047). No serious adverse events occurred due to tacrolimus or immunomodulator, and immunomodulator use did not increase the incidence of adverse events caused by tacrolimus. CONCLUSION: Our data suggest that the use of immunomodulators to maintain remission after tacrolimus therapy is beneficial for patients with ulcerative colitis. |
format | Online Article Text |
id | pubmed-6746627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-67466272019-09-17 Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis Nishida, Yu Hosomi, Shuhei Yamagami, Hirokazu Sugita, Naoko Itani, Shigehiro Yukawa, Tomomi Otani, Koji Nagami, Yasuaki Tanaka, Fumio Taira, Koichi Kamata, Noriko Kakimoto, Kazuki Tanigawa, Tetsuya Watanabe, Toshio Fujiwara, Yasuhiro Intern Med Original Article OBJECTIVE: The need for and efficacy of immunomodulators for maintaining remission after tacrolimus therapy have not been sufficiently defined. This study evaluated the efficacy of immunomodulators for maintaining remission in patients with ulcerative colitis after tacrolimus therapy. METHODS: Patients with active ulcerative colitis who started oral tacrolimus between January 2009 and September 2017 and were responsive were retrospectively evaluated. Long-term outcomes were compared using Cox proportional hazard regression with inverse probability of treatment weighting. RESULTS: Among the 63 patients in the study, 45 received immunomodulators. During the follow-up, 30 patients (47.6%) experienced a relapse. The relapse-free survival rate was significantly worse in the group that did not receive immunomodulators than in those that did (p=0.01, log-rank test); the 2-year relapse-free rates were 22.5% and 63.6% in the non-immunomodulator and immunomodulator groups, respectively. A multivariate analysis showed immunomodulator treatment to be an independent protective factor for clinical relapse (adjusted hazard ratio: 0.35, 95% confidence interval: 0.16-0.78, p=0.01). A Cox regression analysis using inverse probability of treatment weighting also showed that immunomodulator maintenance therapy was correlated with a longer relapse-free survival (hazard ratio: 0.31, 95% confidence interval: 0.15-0.64, p<0.01), A similar response was also observed in non-steroid-dependent patients (hazard ratio: 0.36, 95% confidence interval: 0.14-0.99, p=0.047). No serious adverse events occurred due to tacrolimus or immunomodulator, and immunomodulator use did not increase the incidence of adverse events caused by tacrolimus. CONCLUSION: Our data suggest that the use of immunomodulators to maintain remission after tacrolimus therapy is beneficial for patients with ulcerative colitis. The Japanese Society of Internal Medicine 2019-05-22 2019-08-15 /pmc/articles/PMC6746627/ /pubmed/31118391 http://dx.doi.org/10.2169/internalmedicine.2632-19 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Nishida, Yu Hosomi, Shuhei Yamagami, Hirokazu Sugita, Naoko Itani, Shigehiro Yukawa, Tomomi Otani, Koji Nagami, Yasuaki Tanaka, Fumio Taira, Koichi Kamata, Noriko Kakimoto, Kazuki Tanigawa, Tetsuya Watanabe, Toshio Fujiwara, Yasuhiro Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title_full | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title_fullStr | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title_full_unstemmed | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title_short | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
title_sort | azathioprine is useful for maintaining long-term remission induced by tacrolimus for the treatment of ulcerative colitis: an inverse probability of a treatment weighing analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746627/ https://www.ncbi.nlm.nih.gov/pubmed/31118391 http://dx.doi.org/10.2169/internalmedicine.2632-19 |
work_keys_str_mv | AT nishidayu azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT hosomishuhei azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT yamagamihirokazu azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT sugitanaoko azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT itanishigehiro azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT yukawatomomi azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT otanikoji azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT nagamiyasuaki azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT tanakafumio azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT tairakoichi azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT kamatanoriko azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT kakimotokazuki azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT tanigawatetsuya azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT watanabetoshio azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis AT fujiwarayasuhiro azathioprineisusefulformaintaininglongtermremissioninducedbytacrolimusforthetreatmentofulcerativecolitisaninverseprobabilityofatreatmentweighinganalysis |